Activation of CD8 + T Cells Contributes to Antitumor Effects of CDK4/6 Inhibitors plus MEK Inhibitors

Concurrent MEK and CDK4/6 inhibition shows promise in clinical trials for patients with advanced-stage mutant / solid tumors. The effects of CDK4/6 inhibitor (CDK4/6i) in combination with BRAF/MEK-targeting agents on the tumor immune microenvironment are unclear, especially in melanoma, for which im...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Cancer immunology research 2020-09, Vol.8 (9), p.1114-1121
Hauptverfasser:	Teh, Jessica L F, Erkes, Dan A, Cheng, Phil F, Tiago, Manoela, Wilski, Nicole A, Field, Conroy O, Chervoneva, Inna, Levesque, Mitch P, Xu, Xiaowei, Dummer, Reinhard, Aplin, Andrew E
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!